The New England journal of medicine, 2023-04, Vol.388 (16), p.1465-1477
- Walsh, Edward E.
- Pérez Marc, Gonzalo
- Zareba, Agnieszka M.
- Falsey, Ann R.
- Jiang, Qin
- Patton, Michael
- Polack, Fernando P.
- Llapur, Conrado
- Doreski, Pablo A.
- Ilangovan, Kumar
- Rämet, Mika
- Fukushima, Yasushi
- Hussen, Nazreen
- Bont, Louis J.
- Cardona, Jose
- DeHaan, Elliot
- Castillo Villa, Giselle
- Ingilizova, Marinela
- Eiras, Daniel
- Mikati, Tarek
- Shah, Rupal N.
- Schneider, Katherine
- Cooper, David
- Koury, Kenneth
- Lino, Maria-Maddalena
- Anderson, Annaliesa S.
- Jansen, Kathrin U.
- Swanson, Kena A.
- Gurtman, Alejandra
- Gruber, William C.
- Schmoele-Thoma, Beate
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Walsh, Edward E.
- Pérez Marc, Gonzalo
- Zareba, Agnieszka M.
- Falsey, Ann R.
- Jiang, Qin
- Patton, Michael
- Polack, Fernando P.
- Llapur, Conrado
- Doreski, Pablo A.
- Ilangovan, Kumar
- Rämet, Mika
- Fukushima, Yasushi
- Hussen, Nazreen
- Bont, Louis J.
- Cardona, Jose
- DeHaan, Elliot
- Castillo Villa, Giselle
- Ingilizova, Marinela
- Eiras, Daniel
- Mikati, Tarek
- Shah, Rupal N.
- Schneider, Katherine
- Cooper, David
- Koury, Kenneth
- Lino, Maria-Maddalena
- Anderson, Annaliesa S.
- Jansen, Kathrin U.
- Swanson, Kena A.
- Gurtman, Alejandra
- Gruber, William C.
- Schmoele-Thoma, Beate
- Titel
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
- Ist Teil von
- The New England journal of medicine, 2023-04, Vol.388 (16), p.1465-1477
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2213836Titel-ID: cdi_proquest_miscellaneous_2797147177
- Format
- –
- Schlagworte
- Adverse events, Aged, Aging, Aging General, Antibodies, Viral, Antigens, Chronic illnesses, Coronaviruses, COVID-19, Double-Blind Method, F protein, Geriatrics, Global Health, Hepatitis, Humans, Immunization, Infections, Infectious Disease, Infectious Disease General, Influenza, Injection, Injections, Intramuscular, Middle Aged, Older people, Placebos, Respiratory diseases, Respiratory syncytial virus, Respiratory Syncytial Virus Infections - diagnosis, Respiratory Syncytial Virus Infections - epidemiology, Respiratory Syncytial Virus Infections - prevention & control, Respiratory Syncytial Virus Vaccines - administration & dosage, Respiratory Syncytial Virus Vaccines - adverse effects, Respiratory Syncytial Virus Vaccines - therapeutic use, Respiratory tract, Respiratory Tract Infections - diagnosis, Respiratory Tract Infections - epidemiology, Respiratory Tract Infections - prevention & control, Safety, Seasons, Treatment Outcome, Vaccine Efficacy, Vaccines, Vaccines, Combined - administration & dosage, Vaccines, Combined - adverse effects, Vaccines, Combined - therapeutic use, Viral Infections